.png)
Japan Drug Delivery Devices Market
Japan’s drug delivery devices market accounted USD XX billion in 2016 and is expected to reach USD XX billion by 2020, growing at a CAGR of XX% during the forecast period. Japan has one of the world’s most advanced healthcare facilities. The healthcare administration in Japan is also becoming a model for many developing nations.
Japan Drug Delivery Devices Market-Market Dynamics
The report details several factors driving and restraining the market, some of which are listed below.
Drivers
- Increased prevalence of chronic diseases
- Advances in drug delivery system
- Increase in individual therapy
- Increased understanding about drug metabolism among the population
- Increasing demand for generic drugs
- Requirement of controlled drug release
Restraints
Product recalls and stringent regulatory framework are turning out to be restraints for this market.
Japan’s drug delivery market has been segmented into oral drug delivery systems, nasal drug delivery system, pulmonary drug delivery system, injectable drug delivery, ocular drug delivery, topical drug delivery, transmucosal drug delivery and implantable drug delivery. The segmentation on oral drug delivery system is sub-divided into solid oral drugs (includes tablets, capsules, powders, and pills), liquid oral drugs (includes syrups and solutions), semi-solid oral drugs (includes gels, emulsions, suspensions, and elixirs). The segmentation on nasal drug delivery systems has been subdivided into nasal drops, nasal sprays, nasal powders, nasal gels. The segmentation on pulmonary drug delivery systems includes metered dose inhalers, dry powder inhalers, and nebulizers. The segmentation on injectable drug delivery has been further segmented into general injectable, self -injection device, needle-free injectors, auto-injectors, and pen injectors.
The injectable drug delivery segment has also been sub-divided based on materials, products (includes fillable syringe, and prefilled syringes) and usability (includes reusable syringe and disposable syringes). The segmentation on ocular drug delivery includes liquid ocular drug delivery, semi-solid ocular drug delivery, and ocular devices. The segmentation based on topical drug delivery has been segmented into liquid topical drug delivery (includes suspensions and solutions), semi-solid topical drug delivery (includes creams, gels, pastes, ointments, and lotions), and solid topical drug delivery (includes suppositories and powders). The segmentation on transmucosal drug delivery has been segmented into buccal drug delivery, sublingual drug delivery, rectal transmucosal drug delivery, and vaginal transmucosal drug delivery.
Some of the key players in the market are:
- 3M Company
- F. Hoffmann- La Roche Ltd.
- GlaxoSmithKline
- Johnson and Johnson
- Novartis AG
- Pfizer
- Sanofi
Key Deliverables of the Study
- Market definition along with identification of key drivers and restraints for the market.
- Market analysis for Japan’s drug delivery devices market, with region-specific assessments and competition analysis.
- Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market.
- Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
- Identification and analysis of the macro and micro factors that affect Japan’s drug delivery devices market on a regional scale.
- A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Application of Drug delivery devices
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value-Chain Analysis
5.6 Product Life-Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter’s Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat of New Entrants
5.9.4 Threat of Substitute Products and Services
5.9.5 Competitive Rivalry within the Industry
6. Market Drivers, Restraints, and Opportunities
6.1 Market Drivers
6.1.1 Increasing Prevalence of Chronic Diseases
6.1.2 Advancement in Drug Delivery Systems
6.1.3 Increasing Demand for Generic Drugs
6.1.4 Advancement in Self-Administration and Home Care Drug Delivery
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.2.2 Product Recalls
6.3 Opportunities
6.3.1 Unmet Medical Needs
7. Market Segmentation
7.1 Introduction
7.2 Oral Drug Delivery System
7.2.1 Solid Oral Drugs
7.2.1.1 Tablets
7.2.1.2 Capsules
7.2.1.3 Powders
7.2.1.4 Pills
7.2.2 Liquid Oral Drugs
7.2.2.1 Syrups
7.2.2.2 Solutions
7.2.3 Semi-Solid Oral Drugs
7.2.3.1 Gels
7.2.3.2 Emulsions
7.2.3.3 Suspensions
7.2.3.4 Elixers
7.3 Nasal Drug Delivery
7.3.1 Nasal Drops
7.3.2 Nasal Sprays
7.3.3 Nasal Powders
7.3.4 Nasal Gels
7.4 Pulmonary Drug Delivery
7.4.1 Metered Dose Inhalers
7.4.2 Dry Powder Inhalers
7.4.3 Nebulizers
7.5 Injectable Drug Delivery
7.5.1 General Injectables
7.5.2 Self -Injection Device
7.5.3 Needle Free injectors
7.5.4 Autoinjectors
7.5.5 Pen Injectors
7.5.6 Wearable Injectors
7.5.7 By Material
7.5.7.1 Glass
7.5.7.2 Plastic
7.5.8 By Product
7.5.8.1 Fillable Syringes
7.5.8.2 Prefilled Syringes
7.5.9 By Usability
7.5.9.1 Reusable Syringes
7.5.9.2 Disposable Syringe
7.6 Ocular Drug Delivery
7.6.1 Liquid Ocular Drug Delivery
7.6.2 Semi-solid Ocular Drug delivery
7.6.3 Ocular Devices
7.7 Topical Drug Delivery
7.7.1 Liquid Topical Drug Delivery
7.7.1.1 Suspensions
7.7.1.2 Solutions
7.7.2 Semi-Solid Topical Drug Delivery
7.7.2.1 Creams
7.7.2.2 Gels
7.7.2.3 Pastes
7.7.2.4 Ointments
7.7.2.5 Lotions
7.7.3 Solid Topical Drug Delivery
7.7.3.1 Suppositories
7.7.3.2 Powders
7.8 Transmucosal Drug Delivery
7.8.1 Buccal Drug Delivery
7.8.2 Sublingual Drug Delivery
7.8.3 Rectal Transmucosal Drug Delivery
7.8.4 Vaginal Transmucosal Drug Delivery
7.9 Implantable Drug Delivery
8. Market Segmentation by Geography
8.1 Introduction
8.2 Japan
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Sanofi
10.2 Johnson and Johnson
10.3 Novartis AG
10.4 Pfizer
10.5 F. Hoffmann- La Roche Ltd.
10.6 3M Company
10.7 GlaxoSmithKline
10.8 Merck & Co. Inc.
10.9 Bayer AG
10.10 B Braun Melsungen AG
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
